💊 More research readouts on Orforglipron

The trials are going well, and Orforglipron continues to be effective.

Orforglipron is Eli Lilly’s oral GLP1 — due to come out in 2026 (and sail through FDA approval, according to the comments of Eli Lilly executives), and massively change the GLP1 landscape.

Up until now there have been many announcements and partial readouts of Orforglipron — we keep up with them because being able to gauge all the new GLP1 formulations against each other is important. This readout is even more important, because it’s triggered regulatory submissions for Eli Lilly! FDA approval by 2026 or even sooner is actually possible.